S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:CALA - Calithera Biosciences Stock Price, Forecast & News

$4.54
+0.03 (+0.67 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$4.45
Now: $4.54
$4.60
50-Day Range
$2.71
MA: $3.83
$4.92
52-Week Range
$2.45
Now: $4.54
$6.90
Volume150,891 shs
Average Volume307,839 shs
Market Capitalization$244.14 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.25 million
Book Value$3.32 per share

Profitability

Net Income$-54,630,000.00

Miscellaneous

Employees79
Market Cap$244.14 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.


Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.07. View Calithera Biosciences' Earnings History.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Calithera Biosciences.

What price target have analysts set for CALA?

3 Wall Street analysts have issued 1 year price targets for Calithera Biosciences' shares. Their forecasts range from $7.00 to $8.00. On average, they expect Calithera Biosciences' stock price to reach $7.50 in the next year. This suggests a possible upside of 65.2% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.

What is the consensus analysts' recommendation for Calithera Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.

Has Calithera Biosciences been receiving favorable news coverage?

Media stories about CALA stock have been trending neutral on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Calithera Biosciences earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Calithera Biosciences.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a increase in short interest in November. As of November 29th, there was short interest totalling 1,900,000 shares, an increase of 5.6% from the November 14th total of 1,800,000 shares. Based on an average trading volume of 418,400 shares, the days-to-cover ratio is currently 4.5 days. Currently, 6.8% of the company's stock are short sold. View Calithera Biosciences' Current Options Chain.

Who are some of Calithera Biosciences' key competitors?

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and Synergy Pharmaceuticals (SGYP).

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the folowing people:
  • Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)
  • Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)
  • Dr. Keith Orford, Chief Medical Officer (Age 47)
  • Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)
  • Ms. Jennifer McNealey, VP of Investor Relations & Strategy

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (2.23%), State Street Corp (1.37%), Man Group plc (0.36%), Millennium Management LLC (0.24%), California State Teachers Retirement System (0.14%) and Rhumbline Advisers (0.11%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Susan Molineaux and Value Fund L P Biotechnology. View Institutional Ownership Trends for Calithera Biosciences.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Man Group plc, Assenagon Asset Management S.A. and Barclays PLC. View Insider Buying and Selling for Calithera Biosciences.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, Virtu Financial LLC, California State Teachers Retirement System, Grimes & Company Inc., Wedbush Securities Inc. and Rhumbline Advisers. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, Susan Molineaux and Value Fund L P Biotechnology. View Insider Buying and Selling for Calithera Biosciences.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $4.54.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $244.14 million and generates $22.25 million in revenue each year. The biotechnology company earns $-54,630,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe.View Additional Information About Calithera Biosciences.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is http://www.calithera.com/.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]


MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  293 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  518
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel